COVID-19 Response (VI): Nasal Vaccine Development
$2,906,106.67
Grant Value
2021-22
Fiscal Year
Description
Development of a Nasal Vaccine for the prevention of coronavirus disease 2019 due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
9298436 Canada Inc.
Operating as: Inspirevax
Location
Kirkland, QC H9J 2K6
Agreement Details
Number: 957294
Reference: 172-2021-2022-Q2-957294
Timeline
Start: Sept. 24, 2020
End: Nov. 30, 2021
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Manufacturing (325410)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share